INTRODUCTION: Osteonecrosis of the jaw (ONJ) is a serious side-effect of intravenous nitrogen-containing bisphosphonate therapy frequently used in the treatment of malignant diseases. Despite numerous case series published so far studies with detailed investigations into risk factors, the precise localization of ONJ and impact of ONJ on the oncological treatment remain sparse. PATIENTS AND METHODS: This single-centre study collated medical records (2003-2009) of all patients that suffered from ONJ within the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Germany. In total, 126 patients fulfilled the case criteria of ONJ and were examined clinically. The complete medical history including detailed questionnaires was collected of 66 patients, focussing in particular on the identification of underlying risk factors, clinical features, ONJ localization as well as the impact on the oncological treatment. RESULTS: The majority of ONJ cases occurred in patients suffering from malignant diseases (n=117; 92.8%), in particular breast cancer (n=57; 45.2%), multiple myeloma (n=37; 29.4%) and prostate cancer (n=13; 10.3%), all received nitrogen-containing bisphosphonates intravenously. ONJ was also diagnosed in 9 patients (7.1%) suffering from osteoporosis or rheumatoid arthritis. The most prevalent clinical feature was exposed necrotic bone (93.9%) in the oral cavity which was accompanied in 78.8% of cases by pain. A predilection for the mandible and in particular for molar and premolar regions in both jaws was shown. Although no recommendation concerning the oncologic treatment was made, the manifestation of ONJ resulted (in a significant proportion of the patients) in a change of medication and schedule. The most frequent co-medications were steroids and anti-angiogenetic drugs, such as thalidomide. DISCUSSION: The predilection for mandibular molar and premolar regions, and the infectious conditions that often precede the onset of ONJ support recent pathogenesis theories stating that local inflammation and associated pH-changes may trigger the release and activation of nitrogen-containing bisphosphonates ultimately resulting in necrosis. CONCLUSION: The development of ONJ has a multi-factorial aetiology and the clinical presentation can vary markedly. ONJ cannot only impair the quality of life but also the treatment of the underlying disease.
INTRODUCTION:Osteonecrosis of the jaw (ONJ) is a serious side-effect of intravenous nitrogen-containing bisphosphonate therapy frequently used in the treatment of malignant diseases. Despite numerous case series published so far studies with detailed investigations into risk factors, the precise localization of ONJ and impact of ONJ on the oncological treatment remain sparse. PATIENTS AND METHODS: This single-centre study collated medical records (2003-2009) of all patients that suffered from ONJ within the Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University of Munich, Germany. In total, 126 patients fulfilled the case criteria of ONJ and were examined clinically. The complete medical history including detailed questionnaires was collected of 66 patients, focussing in particular on the identification of underlying risk factors, clinical features, ONJ localization as well as the impact on the oncological treatment. RESULTS: The majority of ONJ cases occurred in patients suffering from malignant diseases (n=117; 92.8%), in particular breast cancer (n=57; 45.2%), multiple myeloma (n=37; 29.4%) and prostate cancer (n=13; 10.3%), all received nitrogen-containing bisphosphonates intravenously. ONJ was also diagnosed in 9 patients (7.1%) suffering from osteoporosis or rheumatoid arthritis. The most prevalent clinical feature was exposed necrotic bone (93.9%) in the oral cavity which was accompanied in 78.8% of cases by pain. A predilection for the mandible and in particular for molar and premolar regions in both jaws was shown. Although no recommendation concerning the oncologic treatment was made, the manifestation of ONJ resulted (in a significant proportion of the patients) in a change of medication and schedule. The most frequent co-medications were steroids and anti-angiogenetic drugs, such as thalidomide. DISCUSSION: The predilection for mandibular molar and premolar regions, and the infectious conditions that often precede the onset of ONJ support recent pathogenesis theories stating that local inflammation and associated pH-changes may trigger the release and activation of nitrogen-containing bisphosphonates ultimately resulting in necrosis. CONCLUSION: The development of ONJ has a multi-factorial aetiology and the clinical presentation can vary markedly. ONJ cannot only impair the quality of life but also the treatment of the underlying disease.
Authors: D Yoshiga; M Sasaguri; K Matsuo; S Kokuryou; M Habu; M Oda; M Kodama; H Tsurushima; O Sakaguchi; T Sakurai; J Tanaka; Y Morimoto; I Yoshioka; K Tominaga Journal: Osteoporos Int Date: 2015-06-03 Impact factor: 4.507
Authors: L Lo Russo; D Ciavarella; C Buccelli; O Di Fede; G Campisi; L Lo Muzio; G Pellegrino; P Di Lorenzo Journal: Br Dent J Date: 2014-09 Impact factor: 1.626
Authors: Paula Baptistella de Lima; Veruska Lima Moura Brasil; Jurema Freire Lisboa de Castro; Flávia Maria de Moraes Ramos-Perez; Fábio Abreu Alves; Maria Luiza dos Anjos Pontual; Danyel Elias da Cruz Perez Journal: Support Care Cancer Date: 2015-03-11 Impact factor: 3.603
Authors: Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis Journal: Bone Date: 2016-06-18 Impact factor: 4.398
Authors: Francisco Javier Manzano-Moreno; Javier Ramos-Torrecillas; Elvira de Luna-Bertos; Rebeca Illescas-Montes; Timothy R Arnett; Concepción Ruiz; Olga García-Martínez Journal: Clin Oral Investig Date: 2018-06-06 Impact factor: 3.573
Authors: Richard C Cardoso; Peter J Gerngross; Theresa M Hofstede; Donna M Weber; Mark S Chambers Journal: Support Care Cancer Date: 2013-09-20 Impact factor: 3.603
Authors: Maria Del Pilar Rodríguez-Sánchez; Cristian Statkievicz; João Martins de Mello-Neto; Luan Felipe Toro; Ana Paula Farnezzi Bassi; Valdir Gouveia Garcia; Letícia Helena Theodoro; Edilson Ervolino Journal: J Lasers Med Sci Date: 2020-01-18
Authors: Oliver Ristow; Carlos Gerngroß; Markus Schwaiger; Bettina Hohlweg-Majert; Melanie Ristow; Steffen Koerdt; Roswitha Schuster; Sven Otto; Christoph Pautke Journal: J Cancer Res Clin Oncol Date: 2014-01-28 Impact factor: 4.553